Objective Anlotinib,an oral vascular endothelial growth factor receptor 2(VEGFR2)inhibitor,has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays,and has been recommended as third-line tre...Objective Anlotinib,an oral vascular endothelial growth factor receptor 2(VEGFR2)inhibitor,has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays,and has been recommended as third-line treatment agent in non-oncogene driven non-small cell lung cancer(NSCLC).This prospective study aimed to investigate the efficacy and safety of anlotinib plus S-1 for third-or later-line treatment in patients with advanced NSCLC.Methods Patients with histologically or cytologically confirmed NSCLC,and documented disease progression following second-line chemotherapy,and/or epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)treatment were enrolled in this study.The patients were treated anlotinib(8 mg daily d 1–14)and S-1(60 mg/m^2 d 1–14)and the treatment was repeated every 3 weeks.Treatment was continued until disease progression or unacceptable toxicity occurred.The objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),and adverse events(AEs)were reviewed and evaluated.Results Forty-one patients were enrolled in the study between June 2018 and December 2018.The total ORR and DCR were 26.8%and 80.5%,respectively.The median PFS was 5.2 months[95%confidence interval(CI),3.9 to 6.6 months].In the univariate analysis,there was a significant difference in the median PFS between patients with brain metastases and those without brain metastases(4.8 months vs 5.9 months,respectively;P=0.039).The Eastern Cooperative Oncology Group(ECOG)performance status(P=0.002),lines of therapy(P=0.015),and therapeutic evaluation(P=0.014)were independent factors that influenced PFS.The most common AEs were hypertension,proteinuria,myelosuppression,gastrointestinal reactions,fatigue,and mucositis.Conclusion Anlotinib plus S-1 is an effective and safe regimen for advanced NSCLC as third-or later-line therapy.展开更多
Compared with best supportive care,chemotherapy can prolong survival a nd improve quality of life,and symptoms associated with society activities and disease.Chemotherapy can improve quality of life of patients with e...Compared with best supportive care,chemotherapy can prolong survival a nd improve quality of life,and symptoms associated with society activities and disease.Chemotherapy can improve quality of life of patients with effective treatme nt and stable treatment.Treatment benefit was often underestimated using clin ical relief rate,so which should not chosen as index for evaluating effec t of palliative treatment.So for pat ients with poor status ,and objective of re lieving symptoms,short term,low-d ose chemotherapy should be suggeste d due to its characteristic of low cost,short inhospitalization time,and f avorable improvement of quality of l ife.For patients with good conditio n in limited advanced stage,radical treatment is objective,and hence single chemotherapy of standard dose o r chemotherapy combining radiotherapy should be suggested.展开更多
One hundred years ago, the first patients with lung cancer have been reported （1）. Since then long term survival in patients with lung cancer remains disappointing, and this is not only due to the delayed diagnosis ...One hundred years ago, the first patients with lung cancer have been reported （1）. Since then long term survival in patients with lung cancer remains disappointing, and this is not only due to the delayed diagnosis but also to the dismal survival of the 70%-75% inoperable patients.展开更多
基金Supported by a grant from the Youth National Science Foundation of China(No.61702164)。
文摘Objective Anlotinib,an oral vascular endothelial growth factor receptor 2(VEGFR2)inhibitor,has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays,and has been recommended as third-line treatment agent in non-oncogene driven non-small cell lung cancer(NSCLC).This prospective study aimed to investigate the efficacy and safety of anlotinib plus S-1 for third-or later-line treatment in patients with advanced NSCLC.Methods Patients with histologically or cytologically confirmed NSCLC,and documented disease progression following second-line chemotherapy,and/or epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)treatment were enrolled in this study.The patients were treated anlotinib(8 mg daily d 1–14)and S-1(60 mg/m^2 d 1–14)and the treatment was repeated every 3 weeks.Treatment was continued until disease progression or unacceptable toxicity occurred.The objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),and adverse events(AEs)were reviewed and evaluated.Results Forty-one patients were enrolled in the study between June 2018 and December 2018.The total ORR and DCR were 26.8%and 80.5%,respectively.The median PFS was 5.2 months[95%confidence interval(CI),3.9 to 6.6 months].In the univariate analysis,there was a significant difference in the median PFS between patients with brain metastases and those without brain metastases(4.8 months vs 5.9 months,respectively;P=0.039).The Eastern Cooperative Oncology Group(ECOG)performance status(P=0.002),lines of therapy(P=0.015),and therapeutic evaluation(P=0.014)were independent factors that influenced PFS.The most common AEs were hypertension,proteinuria,myelosuppression,gastrointestinal reactions,fatigue,and mucositis.Conclusion Anlotinib plus S-1 is an effective and safe regimen for advanced NSCLC as third-or later-line therapy.
文摘Compared with best supportive care,chemotherapy can prolong survival a nd improve quality of life,and symptoms associated with society activities and disease.Chemotherapy can improve quality of life of patients with effective treatme nt and stable treatment.Treatment benefit was often underestimated using clin ical relief rate,so which should not chosen as index for evaluating effec t of palliative treatment.So for pat ients with poor status ,and objective of re lieving symptoms,short term,low-d ose chemotherapy should be suggeste d due to its characteristic of low cost,short inhospitalization time,and f avorable improvement of quality of l ife.For patients with good conditio n in limited advanced stage,radical treatment is objective,and hence single chemotherapy of standard dose o r chemotherapy combining radiotherapy should be suggested.
文摘One hundred years ago, the first patients with lung cancer have been reported （1）. Since then long term survival in patients with lung cancer remains disappointing, and this is not only due to the delayed diagnosis but also to the dismal survival of the 70%-75% inoperable patients.
